A new screening assay reveals that aminoglycoside antibiotics interfere with the Tau/MDM2 interaction
Sola, M.; Ciccaldo, M.; Paganetti, P.; Papin, S.
Show abstract
MAPT gene mutations cause some neurodegenerative tauopathies and the MAPT-encoded protein Tau is deposited in neurofibrillary tangles, hallmarks of this disease family. In addition to its canonical function in regulating microtubule dynamics, Tau modulates chromatin compaction, gene expression, and the cellular response to DNA damage. During the DNA damage response, Tau positively modulates P53 by binding to MDM2 thereby preventing P53 inactivation and degradation. The aberrant presence of both MDM2 associated to neurofibrillary tangles and of P53 misfolding in brains affected by neurodegenerative diseases suggests that the sequestration of MDM2 may prevent P53 clearance in tauopathies and so contribute to progressive neuronal dysfunction and death. Following this evidence, a pharmacological inhibition of the Tau/MDM2 interaction may represent a viable strategy to reduce P53-dependent cell damage in brain disorders. With the screening FDA-approved drugs and natural compounds, we discovered that members of the aminoglycoside antibiotic family antagonize the Tau/MDM2 interaction. The use of these reagents may advance the understanding of the implication of the Tau/MDM2/P53 axis in neurodegeneration models. However, their unfavorable pharmacokinetic properties may limit their systemic use when targeting the brain.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Time-resolved FRET screening identifies small molecular modifiers of mutant Huntingtin conformational inflexibility in patient-derived cells 93%
- TREM2 Hit Discovery Using TRIC Technology: A Proof-of-Concept High-Throughput Screening Approach 92%
- CETSA MS profiling for a comparative assessment of FDA approved antivirals repurposed for COVID-19 therapy identifies Trip13 as a Remdesivir off-target 92%
Similar papers in this journal
- Exifone is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration 96%
- A patient-derived blood-brain barrier model for screening copper bis(thiosemicarbazone) complexes as potential therapeutics in Alzheimer's disease 93%
- Development of a PC12 cell-based assay for in vitro screening of catechol-O-methyltransferase inhibitors 92%
Similar papers in this journal
- An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19 92%
- Catechol-Containing Compounds are a Broad Class of Amyloid Inhibitors: II. Rosmarinic Acid Potently Detoxifies Amylin Amyloid and Ameliorates Diabetic Pathology in HIP Rats 92%
- Optimization and evaluation of complementary degrader discovery assays for application in screening 91%
Similar papers in this journal
- A β-secretase modulator decreases Tau pathology and preserves short-term memory in a mouse model of neurofibrillary degeneration 95%
- Xenobiotic compounds modulate cytotoxicity of Aβ amyloids and interact with neuroprotective chaperone L-PGDS 92%
- Dual blockade of misfolded alpha-sarcoglycan degradation by bortezomib and givinostat combination 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.